Obesity News

Published results showed exercise in combination with glucagon-like peptide-1 receptor agonist treatment may be an effective weight loss strategy that preserves clinically relevant site-specific bone mineral density.

This year’s American Society for Nutrition Scientific Sessions and Annual Meeting will take place in person in Chicago from June 29 to July 2.

A 5:2 intermittent fasting diet combined with meal replacement resulted in greater weight loss and better glycemic control compared with antidiabetic medications in patients with early-stage type 2 diabetes, data from the EARLY study showed.

ORLANDO — Semaglutide reduces risk for cardiovascular events among adults with overweight or obesity and preexisting cardiovascular disease, regardless of baseline HbA1c or change in HbA1c, according to data from the SELECT trial.

In patients with obesity-driven heart failure with preserved ejection fraction, semaglutide 2.4 mg was associated with more improvement in NYHA functional class compared with placebo, according to new data from the STEP-HFpEF trials.

Gestational weight gain that exceeded National Academy of Medicine guidelines occurred among 75% of pregnant women who were TRICARE beneficiaries and gave birth in 2018 or 2019, according to findings published in Obesity.

ORLANDO — Among adults with obesity-related heart failure with preserved ejection fraction, women taking semaglutide lost significantly more weight than men, but greater weight loss did not result in extra health benefits for women vs. men.

ORLANDO — Adults with obesity who reduce their body weight lower their odds for developing an obesity-related cancer, according to data presented at the American Diabetes Association Scientific Sessions.

ORLANDO — Race-conscious medicine can help to identify those at higher risk for prediabetes and diabetes; however, this method can exacerbate racism and impede health equity, according to two speakers.

ORLANDO — The GIP/GLP-1 dual agonist tirzepatide reduced symptoms of obstructive sleep apnea and improved multiple cardiometabolic markers for adults with obesity and obstructive sleep apnea, according to data from the SURMOUNT-OSA trial.